PMID- 37510134
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230801
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 13
IP  - 14
DP  - 2023 Jul 17
TI  - Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: 
      From Risk Factors to Diagnosis, Biomarkers and Therapy.
LID - 10.3390/diagnostics13142390 [doi]
LID - 2390
AB  - Triple-negative breast cancer (TNBC) is usually the most malignant and aggressive 
      mammary epithelial tumor characterized by the lack of expression for estrogen 
      receptors and progesterone receptors, and the absence of epidermal growth factor 
      receptor (HER)2 amplification. Corresponding to 15-20% of all breast cancers and 
      well-known by its poor clinical outcome, this negative receptor expression 
      deprives TNBC from targeted therapy and makes its management therapeutically 
      challenging. Type 2 diabetes mellitus (T2DM) is the most common ageing metabolic 
      disorder due to insulin deficiency or resistance resulting in hyperglycemia, 
      hyperinsulinemia, and hyperlipidemia. Due to metabolic and hormonal imbalances, 
      there are many interplays between both chronic disorders leading to increased 
      risk of breast cancer, especially TNBC, diagnosed in T2DM patients. The purpose 
      of this review is to provide up-to-date information related to epidemiology and 
      clinicopathological features, risk factors, diagnosis, biomarkers, and current 
      therapy/clinical trials for TNBC patients with T2DM compared to non-diabetic 
      counterparts. Thus, in-depth investigation of the diabetic complications on TNBC 
      onset, development, and progression and the discovery of biomarkers would improve 
      TNBC management through early diagnosis, tailoring therapy for a better outcome 
      of T2DM patients diagnosed with TNBC.
FAU - Matou-Nasri, Sabine
AU  - Matou-Nasri S
AUID- ORCID: 0000-0003-4372-2903
AD  - Blood and Cancer Research Department, King Abdullah International Medical 
      Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences 
      (KSAU-HS), Ministry of National Guard Health Affairs (MNG-HA), Riyadh 11481, 
      Saudi Arabia.
AD  - Biosciences Department, Faculty of the School for Systems Biology, George Mason 
      University, Manassas, VA 22030, USA.
FAU - Aldawood, Maram
AU  - Aldawood M
AD  - Blood and Cancer Research Department, King Abdullah International Medical 
      Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences 
      (KSAU-HS), Ministry of National Guard Health Affairs (MNG-HA), Riyadh 11481, 
      Saudi Arabia.
AD  - Post Graduate and Zoology Department, King Saud University, Riyadh 12372, Saudi 
      Arabia.
FAU - Alanazi, Fatimah
AU  - Alanazi F
AD  - Blood and Cancer Research Department, King Abdullah International Medical 
      Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Sciences 
      (KSAU-HS), Ministry of National Guard Health Affairs (MNG-HA), Riyadh 11481, 
      Saudi Arabia.
AD  - Biosciences Department, Faculty of the School for Systems Biology, George Mason 
      University, Manassas, VA 22030, USA.
FAU - Khan, Abdul Latif
AU  - Khan AL
AD  - Tissue Biobank, KAIMRC, MNG-HA, Riyadh 11481, Saudi Arabia.
AD  - Pathology and Clinical Laboratory Medicine, King Abdulaziz Medical City (KAMC), 
      Riyadh 11564, Saudi Arabia.
LA  - eng
GR  - RC15/160/King Abdullah International Medical Research Center/
PT  - Journal Article
PT  - Review
DEP - 20230717
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC10378597
OTO - NOTNLM
OT  - biomarkers
OT  - diagnosis
OT  - prognosis
OT  - risk factors
OT  - therapy
OT  - triple-negative breast cancer
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/29 11:46
MHDA- 2023/07/29 11:47
PMCR- 2023/07/17
CRDT- 2023/07/29 01:16
PHST- 2023/05/15 00:00 [received]
PHST- 2023/06/20 00:00 [revised]
PHST- 2023/06/26 00:00 [accepted]
PHST- 2023/07/29 11:47 [medline]
PHST- 2023/07/29 11:46 [pubmed]
PHST- 2023/07/29 01:16 [entrez]
PHST- 2023/07/17 00:00 [pmc-release]
AID - diagnostics13142390 [pii]
AID - diagnostics-13-02390 [pii]
AID - 10.3390/diagnostics13142390 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2023 Jul 17;13(14):2390. doi: 10.3390/diagnostics13142390.